Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation

Reuters

2025/11/18

Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation

Puma Biotechnology Inc. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584677769"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584677769\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584677769?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584677769","market":"fut","top_or_hot":-1,"title":"Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PBYI\">Puma Biotechnology Inc</a>. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPuma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 06:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PBYI\">Puma Biotechnology Inc</a>. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4H6Yz:1","article_id":"2584677769","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584677769","pubTimestamp":1763418812,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Puma Biotechnology Inc. presented updates on the commercialization of NERLYNX, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PBYI":"Puma Biotechnology Inc"},"translate_title":"Puma Biotechnology在新的公司演示中展示了管道进展和NERLYNX商业更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBYI":0.9},"content_text":"Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    \n\nPuma Biotechnology Inc. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}